Altimmune, Inc.
NASDAQ:ALTBiotechnology
+$0.08 today
- Market cap
- $270.48M
- Beta
- 0.23
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$0.73
Volume 4.69M
Average 3.81M
ALT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Altimmune, Inc.NASDAQ: ALT
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 98.8% from a year ago
Cash & equivalents stood at $97.6M at the end of Q1 FY2026, up 98.8% from a year earlier and up 123.0% from the prior quarter. Over 3 fiscal years it compounded at -26.7% a year.
Context
- Cash & equivalents amounted to 29.1% of total assets at the end of Q1 FY2026, down 2.1 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +98.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 43.76M USD
- Year-over-year change
- +18.5%
- 4-year CAGR
- -30.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43.76M | +18.5% |
| FY2024 | 2024-12-31 | 36.93M | -72.7% |
| FY2023 | 2023-12-31 | 135.12M | +21.6% |
| FY2022 | 2022-12-31 | 111.1M | -41.6% |
| FY2021 | 2021-12-31 | 190.3M | — |
Cash & Equivalents vs competitors
How ALT compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +98.8% is the highest of 9, against a peer median of +1.9%.
- Cash & equivalents amounts to 29.1% of total assets for ALT, versus a peer median of 23.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $276.09M USD | +0.9% | -34.9% | 26.9% | |
| Jun 2026 | $272.64M USD | +85.4% | +212.9% | 19.1% | |
| Dec 2025 | €99.27M EUR | +2.8% | +4.6% | 39.9% | |
| Mar 2026 | $97.6M USD | +98.8% | -26.7% | 29.1% | |
| Mar 2026 | $44.69M USD | +24.6% | -20.7% | 96.4% | |
| Mar 2026 | $34.93M USD | -42.0% | -9.8% | 11.1% | |
| Mar 2026 | $31.12M USD | +32.9% | +3.7% | 13.2% | |
| Mar 2026 | $23.71M USD | -36.1% | -16.4% | 8.6% | |
| Mar 2026 | $1.5M USD | -61.5% | -4.0% | 68.7% | |
| Peer median (excluding ALT) | — | +1.9% | -6.9% | 23.0% | |
Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 190.3M | 111.1M | 135.12M | 36.93M | 43.76M |
| Short-term Investments | 0 | 73.78M | 62.7M | 94.97M | 229.7M |
| Net Receivables | 5.84M | 2.54M | 4.85M | 3.12M | 1.74M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 33.31K | 5.39M | 6.96M | 2.25M | 3M |
| Total Current Assets | 204.13M | 192.81M | 209.63M | 137.25M | 278.19M |
| Property, Plant & Equipment (Net) | 1.45M | 1.08M | 651K | 413K | 312K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 12.42M | 12.42M | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 872K | 615K | 363K | 1.64M | 1.43M |
| Total Non-current Assets | 14.74M | 14.12M | 1.01M | 2.05M | 1.74M |
| Total Assets | 218.87M | 206.93M | 210.64M | 139.31M | 279.93M |
| Account Payables | 2.03M | 4.8M | 2.07M | 211K | 2.72M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 1.17M | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.09M | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 18.28M | 17.05M | 12.14M | 10.47M | 15M |
| Long-term Debt | 0 | 0 | 0 | 0 | 34.29M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 160K |
| Other Non-current Liabilities | 330K | 3.91M | 4.22M | 3.93M | 4.45M |
| Total Non-current Liabilities | 1.45M | 4.58M | 4.4M | 5.33M | 40.04M |
| Total Liabilities | 19.73M | 21.64M | 16.54M | 15.8M | 55.04M |
| Common Stock | 4K | 5K | 7K | 7K | 11K |
| Retained Earnings | (293.17M) | (377.88M) | (466.33M) | (561.39M) | (649.48M) |
| Accumulated OCI | (5.04M) | (5.23M) | (5M) | (4.97M) | (4.93M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 199.14M | 185.29M | 194.1M | 123.51M | 224.89M |
| Total Debt | 1.54M | 1.12M | 671K | 1.68M | 35.69M |
| Net Debt | (188.77M) | (109.97M) | (134.45M) | (35.25M) | (8.07M) |
Altimmune, Inc.
NASDAQ:ALT
Intrinsic Alpha fair value
Locked
Current Price
$1.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.